Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Les outils de gestion documentaire (2/2).

Guillouët S.

Rev Infirm. 2019 Apr;68(250):47-48. doi: 10.1016/j.revinf.2019.03.017. French. No abstract available.

PMID:
31147079
2.

Prendre soin de ceux qui nous soignent.

Guillouët S.

Rev Infirm. 2019 Apr;68(250):1. doi: 10.1016/j.revinf.2019.03.003. French. No abstract available.

PMID:
31147065
3.

Les infirmières coordinatrices.

Guillouët S.

Rev Infirm. 2019 Mar;68(249):15. doi: 10.1016/j.revinf.2019.02.002. French. No abstract available.

PMID:
31056168
4.

Les outils de gestion documentaire (1/2).

Guillouët S.

Rev Infirm. 2019 Feb;68(248):49-50. doi: 10.1016/j.revinf.2019.01.018. French. No abstract available.

PMID:
30955545
5.

Simultaneous Removal And Reinsertion of the PD Catheter in Relapsing Peritonitis.

Viron C, Lobbedez T, Lanot A, Bonnamy C, Ficheux M, Guillouet S, Bechade C.

Perit Dial Int. 2019 May-Jun;39(3):282-288. doi: 10.3747/pdi.2018.00230. Epub 2019 Mar 9.

PMID:
30852521
6.

La navigation dans PubMed (2/2).

Guillouët S.

Rev Infirm. 2018 Dec;67(246):47-48. doi: 10.1016/j.revinf.2018.10.015. French. No abstract available.

PMID:
30591138
7.

Impact of Assisted Peritoneal Dialysis Modality on Outcomes: A Cohort Study of the French Language Peritoneal Dialysis Registry.

Guilloteau S, Lobbedez T, Guillouët S, Verger C, Ficheux M, Lanot A, Béchade C.

Am J Nephrol. 2018;48(6):425-433. doi: 10.1159/000494664. Epub 2018 Nov 21.

PMID:
30463079
8.

La navigation dans PUBMED (1/2).

Guillouët S.

Rev Infirm. 2018 Oct;67(244):47-48. doi: 10.1016/j.revinf.2018.08.015. French. No abstract available.

PMID:
30415692
9.

Innovation en soins et qualité de vie des malades.

Guillouët S.

Rev Infirm. 2018 Oct;67(244):1. doi: 10.1016/j.revinf.2018.08.019. French. No abstract available.

PMID:
30415678
10.

[Therapeutic education of epileptic patients and quality of life].

Ducourtil C, Prevos-Morgant M, Guillouët S.

Rev Infirm. 2018 Aug - Sep;67(243):23-24. doi: 10.1016/j.revinf.2018.07.006. French.

PMID:
30262005
11.

Épilepsie et accompagnement.

Guillouët S.

Rev Infirm. 2018 Aug - Sep;67(243):13. doi: 10.1016/j.revinf.2018.07.002. French. No abstract available.

PMID:
30262001
12.

[18F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [18F]FDG in human xenograft models.

Hovhannisyan N, Fillesoye F, Guillouet S, Ibazizene M, Toutain J, Gourand F, Valable S, Plancoulaine B, Barré L.

Theranostics. 2018 Aug 10;8(16):4563-4573. doi: 10.7150/thno.26754. eCollection 2018.

13.

Alka(e)ne synthesis in Cupriavidus necator boosted by the expression of endogenous and heterologous ferredoxin-ferredoxin reductase systems.

Crépin L, Barthe M, Leray F, Guillouet SE.

Biotechnol Bioeng. 2018 Oct;115(10):2576-2584. doi: 10.1002/bit.26805. Epub 2018 Aug 29.

PMID:
30063082
14.

La recherche documentaire (3/3).

Da Cunha M, Guillouët S.

Rev Infirm. 2018 Jun - Jul;67(242):39-40. doi: 10.1016/j.revinf.2018.03.005. French. No abstract available.

PMID:
29907180
15.

La recherche documentaire (2/3).

Da Cunha M, Guillouët S.

Rev Infirm. 2018 Apr;67(240):43-44. doi: 10.1016/j.revinf.2018.02.016. French. No abstract available.

PMID:
29609793
16.

[Certification, on-the-ground experience of a manager and his team].

Thibault C, Guillouët S, Havin MP.

Rev Infirm. 2018 Mar;67(239):26-28. doi: 10.1016/j.revinf.2018.01.006. French.

PMID:
29525010
17.

Impacts of environmental conditions on product formation and morphology of Yarrowia lipolytica.

Timoumi A, Guillouet SE, Molina-Jouve C, Fillaudeau L, Gorret N.

Appl Microbiol Biotechnol. 2018 May;102(9):3831-3848. doi: 10.1007/s00253-018-8870-3. Epub 2018 Mar 9. Review.

PMID:
29523935
18.

18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients.

Chantepie S, Hovhannisyan N, Guillouet S, Pelage JP, Ibazizene M, Bodet-Milin C, Carlier T, Gac AC, Réboursière E, Vilque JP, Kraeber-Bodéré F, Manrique A, Damaj G, Leporrier M, Barré L.

J Nucl Med. 2018 Sep;59(9):1380-1385. doi: 10.2967/jnumed.117.206920. Epub 2018 Feb 1.

PMID:
29419478
19.

Factors associated with nurse assistance among peritoneal dialysis patients: a cohort study from the French Language Peritoneal Dialysis Registry.

Guillouët S, Lobbedez T, Lanot A, Verger C, Ficheux M, Béchade C.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1446-1452. doi: 10.1093/ndt/gfx338.

PMID:
29294042
20.

Modeling and optimization of lipid accumulation by Yarrowia lipolytica from glucose under nitrogen depletion conditions.

Robles-Rodríguez CE, Muñoz-Tamayo R, Bideaux C, Gorret N, Guillouet SE, Molina-Jouve C, Roux G, Aceves-Lara CA.

Biotechnol Bioeng. 2018 May;115(5):1137-1151. doi: 10.1002/bit.26537. Epub 2018 Jan 31.

PMID:
29288574
21.

Les professionnels impliqués dans la recherche.

Guillouët S.

Rev Infirm. 2017 Dec;66(236):43-44. doi: 10.1016/j.revinf.2017.10.009. French. No abstract available.

PMID:
29179849
22.

Safety of Peritoneal Dialysis after Nonrenal Solid-Organ Transplantation.

Buffet A, Guillouët S, Lobbedez T, Ficheux M, Lanot A, Béchade C.

Perit Dial Int. 2018 Jan-Feb;38(1):37-43. doi: 10.3747/pdi.2017.00125. Epub 2017 Nov 21.

PMID:
29162679
23.

Des perspectives à l’université pour les infirmiers.

Guillouët S.

Rev Infirm. 2017 Nov;66(235):1. doi: 10.1016/j.revinf.2017.09.022. French. No abstract available.

PMID:
29127970
24.

Modulation of the Glycerol Phosphate availability led to concomitant reduction in the citric acid excretion and increase in lipid content and yield in Yarrowia lipolytica.

Sagnak R, Cochot S, Molina-Jouve C, Nicaud JM, Guillouet SE.

J Biotechnol. 2018 Jan 10;265:40-45. doi: 10.1016/j.jbiotec.2017.11.001. Epub 2017 Nov 2.

PMID:
29102548
25.

Expanding the genetic tool box for Cupriavidus necator by a stabilized L-rhamnose inducible plasmid system.

Sydow A, Pannek A, Krieg T, Huth I, Guillouet SE, Holtmann D.

J Biotechnol. 2017 Dec 10;263:1-10. doi: 10.1016/j.jbiotec.2017.10.002. Epub 2017 Oct 4.

PMID:
28988032
26.

Infirmier chercheur, une réalité.

Guillouët S.

Rev Infirm. 2017 Oct;66(234):45-46. doi: 10.1016/j.revinf.2017.07.010. French. No abstract available.

PMID:
28985784
27.

Influence of oxygen availability on the metabolism and morphology of Yarrowia lipolytica: insights into the impact of glucose levels on dimorphism.

Timoumi A, Bideaux C, Guillouet SE, Allouche Y, Molina-Jouve C, Fillaudeau L, Gorret N.

Appl Microbiol Biotechnol. 2017 Oct;101(19):7317-7333. doi: 10.1007/s00253-017-8446-7. Epub 2017 Sep 6.

PMID:
28879478
28.

Over expression of GroESL in Cupriavidus necator for heterotrophic and autotrophic isopropanol production.

Marc J, Grousseau E, Lombard E, Sinskey AJ, Gorret N, Guillouet SE.

Metab Eng. 2017 Jul;42:74-84. doi: 10.1016/j.ymben.2017.05.007. Epub 2017 Jun 4.

PMID:
28591561
29.

Centre characteristics associated with the risk of peritonitis in peritoneal dialysis: a hierarchical modelling approach based on the data of the French Language Peritoneal Dialysis Registry.

Béchade C, Guillouët S, Verger C, Ficheux M, Lanot A, Lobbedez T.

Nephrol Dial Transplant. 2017 Jun 1;32(6):1018-1023. doi: 10.1093/ndt/gfx051.

PMID:
28472525
30.

[18F]Fludarabine-PET in a murine model of multiple myeloma.

Hovhannisyan N, Dhilly M, Fidalgo M, Fillesoye F, Guillouet S, Sola B, Barré L.

PLoS One. 2017 May 4;12(5):e0177125. doi: 10.1371/journal.pone.0177125. eCollection 2017.

31.

Dynamic behavior of Yarrowia lipolytica in response to pH perturbations: dependence of the stress response on the culture mode.

Timoumi A, Cléret M, Bideaux C, Guillouet SE, Allouche Y, Molina-Jouve C, Fillaudeau L, Gorret N.

Appl Microbiol Biotechnol. 2017 Jan;101(1):351-366. doi: 10.1007/s00253-016-7856-2. Epub 2016 Oct 11.

PMID:
27730339
32.

Metabolic engineering of Cupriavidus necator for heterotrophic and autotrophic alka(e)ne production.

Crépin L, Lombard E, Guillouet SE.

Metab Eng. 2016 Sep;37:92-101. doi: 10.1016/j.ymben.2016.05.002. Epub 2016 May 20.

PMID:
27212691
33.

Comparative Analysis between [(18)F]Fludarabine-PET and [(18)F]FDG-PET in a Murine Model of Inflammation.

Hovhannisyan N, Dhilly M, Guillouet S, Leporrier M, Barré L.

Mol Pharm. 2016 Jun 6;13(6):2136-9. doi: 10.1021/acs.molpharmaceut.6b00050. Epub 2016 Apr 25.

PMID:
27080099
34.

Estimation of the Center Effect on Early Peritoneal Dialysis Failure: A Multilevel Modelling Approach.

Guillouët S, Veniez G, Verger C, Béchade C, Ficheux M, Uteza J, Lobbedez T.

Perit Dial Int. 2016 9-10;36(5):519-25. doi: 10.3747/pdi.2015.00245. Epub 2016 Apr 4.

35.

Lipids containing medium-chain fatty acids are specific to post-whole genome duplication Saccharomycotina yeasts.

Froissard M, Canonge M, Pouteaux M, Cintrat B, Mohand-Oumoussa S, Guillouet SE, Chardot T, Jacques N, Casaregola S.

BMC Evol Biol. 2015 May 28;15:97. doi: 10.1186/s12862-015-0369-2.

36.

Evaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapy.

Hovhannisyan N, Guillouet S, Fillesoye F, Dhilly M, Patin D, Galateau F, Leporrier M, Barré L.

EJNMMI Res. 2015 Apr 14;5:23. doi: 10.1186/s13550-015-0101-7. eCollection 2015.

37.

Kinetic and stoichiometric characterization of organoautotrophic growth of Ralstonia eutropha on formic acid in fed-batch and continuous cultures.

Grunwald S, Mottet A, Grousseau E, Plassmeier JK, Popović MK, Uribelarrea JL, Gorret N, Guillouet SE, Sinskey A.

Microb Biotechnol. 2015 Jan;8(1):155-63. doi: 10.1111/1751-7915.12149. Epub 2014 Aug 13.

38.

Isopropanol production with engineered Cupriavidus necator as bioproduction platform.

Grousseau E, Lu J, Gorret N, Guillouet SE, Sinskey AJ.

Appl Microbiol Biotechnol. 2014 May;98(9):4277-90. doi: 10.1007/s00253-014-5591-0. Epub 2014 Mar 7.

PMID:
24604499
39.

D-stat culture for studying the metabolic shifts from oxidative metabolism to lipid accumulation and citric acid production in Yarrowia lipolytica.

Ochoa-Estopier A, Guillouet SE.

J Biotechnol. 2014 Jan 20;170:35-41. doi: 10.1016/j.jbiotec.2013.11.008. Epub 2013 Dec 4.

PMID:
24316225
40.

Impact of oleic acid as co-substrate of glucose on "short" and "long-term" Crabtree effect in Saccharomyces cerevisiae.

Marc J, Feria-Gervasio D, Mouret JR, Guillouet SE.

Microb Cell Fact. 2013 Sep 23;12:83. doi: 10.1186/1475-2859-12-83.

41.

2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.

Dhilly M, Guillouet S, Patin D, Fillesoye F, Abbas A, Gourand F, Tirel O, Galateau F, MacKenzie ET, Dumontet C, Leporrier M, Barré L.

Mol Imaging Biol. 2014 Feb;16(1):118-26. doi: 10.1007/s11307-013-0659-2.

PMID:
23852402
42.

Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.

Guillouet S, Patin D, Tirel O, Delamare J, Gourand F, Deloye JB, Leporrier M, Barré L.

Mol Imaging Biol. 2014 Feb;16(1):28-35. doi: 10.1007/s11307-013-0657-4.

PMID:
23836501
43.

The metabolic costs of improving ethanol yield by reducing glycerol formation capacity under anaerobic conditions in Saccharomyces cerevisiae.

Pagliardini J, Hubmann G, Alfenore S, Nevoigt E, Bideaux C, Guillouet SE.

Microb Cell Fact. 2013 Mar 28;12:29. doi: 10.1186/1475-2859-12-29.

44.

Assessment of Candida shehatae viability by flow cytometry and fluorescent probes.

Monthéard J, Garcier S, Lombard E, Cameleyre X, Guillouet S, Molina-Jouve C, Alfenore S.

J Microbiol Methods. 2012 Oct;91(1):8-13. doi: 10.1016/j.mimet.2012.07.002. Epub 2012 Jul 14.

PMID:
22796678
45.

Dynamic model of temperature impact on cell viability and major product formation during fed-batch and continuous ethanolic fermentation in Saccharomyces cerevisiae.

Amillastre E, Aceves-Lara CA, Uribelarrea JL, Alfenore S, Guillouet SE.

Bioresour Technol. 2012 Aug;117:242-50. doi: 10.1016/j.biortech.2012.04.013. Epub 2012 Apr 13.

PMID:
22617033
46.

Gpd1 and Gpd2 fine-tuning for sustainable reduction of glycerol formation in Saccharomyces cerevisiae.

Hubmann G, Guillouet S, Nevoigt E.

Appl Environ Microbiol. 2011 Sep;77(17):5857-67. doi: 10.1128/AEM.05338-11. Epub 2011 Jul 1.

47.

Kinetic analysis of a Saccharomyces cerevisiae strain adapted for improved growth on glycerol: Implications for the development of yeast bioprocesses on glycerol.

Ochoa-Estopier A, Lesage J, Gorret N, Guillouet SE.

Bioresour Technol. 2011 Jan;102(2):1521-7. doi: 10.1016/j.biortech.2010.08.003. Epub 2010 Aug 13.

PMID:
20869237
48.

Quantitative evaluation of yeast's requirement for glycerol formation in very high ethanol performance fed-batch process.

Pagliardini J, Hubmann G, Bideaux C, Alfenore S, Nevoigt E, Guillouet SE.

Microb Cell Fact. 2010 May 21;9:36. doi: 10.1186/1475-2859-9-36.

49.

Effect of controlled oxygen limitation on Candida shehatae physiology for ethanol production from xylose and glucose.

Fromanger R, Guillouet SE, Uribelarrea JL, Molina-Jouve C, Cameleyre X.

J Ind Microbiol Biotechnol. 2010 May;37(5):437-45. doi: 10.1007/s10295-009-0688-7. Epub 2010 Jan 12.

PMID:
20066468
50.

Fermentative production of L-glycerol 3-phosphate utilizing a Saccharomyces cerevisiae strain with an engineered glycerol biosynthetic pathway.

Popp A, Nguyen HT, Boulahya K, Bideaux C, Alfenore S, Guillouet SE, Nevoigt E.

Biotechnol Bioeng. 2008 Jun 15;100(3):497-505. doi: 10.1002/bit.21777.

PMID:
18438874

Supplemental Content

Loading ...
Support Center